Core Viewpoint - 百奥赛图-B has signed a licensing agreement with German ADC developer Tubulis to utilize its RenMice fully human antibody development platform for innovative ADC therapies, indicating strong international competitiveness and drug conversion potential [1] Group 1: Company Developments - 百奥赛图-B's stock rose over 7% in the afternoon trading session, with a current price of 26.58 HKD and a trading volume of 16.7354 million HKD [1] - The agreement with Tubulis includes an upfront payment, milestone payments for development, regulatory, and commercialization, as well as a single-digit percentage of net sales [1] - On September 4, 百奥赛图-B signed an antibody option and evaluation agreement with Merck to assess antibodies developed using the RenMice platform for advanced solutions like nucleic acid drug delivery [1] Group 2: Market Implications - The agreements with Tubulis and Merck highlight the international competitiveness of 百奥赛图-B's fully human antibody platform and its potential for drug conversion [1]

Core Viewpoint - The company BaiO Saite-B (02135) has signed a licensing agreement with German ADC developer Tubulis, leveraging its RenMice fully human antibody development platform for innovative ADC therapies, which is expected to enhance its market position and revenue potential [1] Group 1: Licensing Agreement with Tubulis - On September 16, BaiO Saite announced a licensing agreement with Tubulis to utilize its RenMice platform for developing ADC therapies, which includes an upfront payment and milestone payments based on development, regulatory, and commercialization achievements, along with a single-digit percentage of net sales [1] - The stock price of BaiO Saite increased by over 7% in the afternoon trading session, reflecting positive market sentiment regarding the agreement [1] Group 2: Previous Agreement with Merck - On September 4, BaiO Saite signed an antibody option and evaluation agreement with Merck to assess the fully human antibodies developed using the RenMice platform for potential applications in nucleic acid drug delivery [1] - The agreements with Tubulis and Merck highlight the international competitiveness and drug conversion potential of BaiO Saite's fully human antibody platform, as stated by the company's Chairman and CEO Shen Yuelai [1]

Core Insights - The company, Baiaosaitu, has secured two significant licensing agreements within a month, highlighting the value of its proprietary RenMice fully human antibody development platform [1][2] - The company has established itself as a leader in the innovative molecular licensing space in China, with a total of 280 licensing projects, including partnerships with seven of the top ten global pharmaceutical companies [2][3] Group 1: Licensing Agreements - On September 16, Baiaosaitu signed an antibody licensing agreement with Tubulis, which will utilize Baiaosaitu's RenMice platform for developing innovative ADC therapies [1] - Just over a week prior, on September 4, Baiaosaitu entered into an antibody option and evaluation agreement with Merck to assess antibodies developed using the RenMice platform [1] - These agreements demonstrate the international competitiveness and drug conversion potential of Baiaosaitu's fully human antibody platform [1] Group 2: Financial Performance - In the first half of the year, Baiaosaitu achieved a revenue of 621 million yuan, representing a year-on-year growth of over 51% [2] - The company's gross margin remained high at approximately 74.4%, with a net profit of 48 million yuan [2] - The stock price of Baiaosaitu increased significantly, from a low of 7.8 HKD per share to a high of 28.58 HKD per share, reflecting a growth of over 320% since the beginning of the year [2] Group 3: Research and Development - Baiaosaitu's R&D expenses for the first half of the year were approximately 209 million yuan, an increase of 29.3% year-on-year [4] - The company has obtained 195 authorized patents and submitted 496 patent applications, focusing on expanding its fully human antibody library [4] - Baiaosaitu aims to enhance its core advantages in target humanized mouse and fully human antibody discovery by integrating AI and automation into its R&D processes [4]